Pretreatment with quercetin prevents changes in lymphocytes E-NTPDase/E-ADA activities and cytokines secretion in hyperlipidemic rats
Autor: | Daniela B.R. Leal, Josiane B.S. Braun, Jader B. Ruchel, Daniela F. Passos, Lívia G. Castilhos, Emerson André Casalli, Alessandra G. Manzoni, Fátima Husein Abdalla |
---|---|
Rok vydání: | 2017 |
Předmět: |
Male
0301 basic medicine Adenosine Deaminase Clinical chemistry Clinical Biochemistry Flavonoid Hyperlipidemias Pharmacology Proinflammatory cytokine 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Hyperlipidemia medicine Animals heterocyclic compounds Lymphocytes cardiovascular diseases Pyrophosphatases Rats Wistar Endothelial dysfunction Molecular Biology chemistry.chemical_classification Cholesterol business.industry nutritional and metabolic diseases Cell Biology General Medicine medicine.disease Rats 030104 developmental biology chemistry Simvastatin 030220 oncology & carcinogenesis Cytokines Quercetin business medicine.drug |
Zdroj: | Molecular and Cellular Biochemistry. 444:63-75 |
ISSN: | 1573-4919 0300-8177 |
Popis: | Hyperlipidemia (HL) is a condition associated with endothelial dysfunction and inflammatory disorders. Purinergic system ectoenzymes play an important role in modulating the inflammatory and immune response. This study investigated whether the preventive treatment with quercetin is able to prevent changes caused by hyperlipidemia in the purinergic system, through the activities of E-NTPDase and E-ADA in lymphocytes, and quantify the nucleotides and nucleoside, and the secretion of anti- and proinflammatory cytokines. Animals were divided into saline/control, saline/quercetin 5 mg/kg, saline/quercetin 25 mg/kg, saline/quercetin 50 mg/kg, saline/simvastatin (0.04 mg/kg), hyperlipidemia, hyperlipidemia/quercetin 5 mg/kg, hyperlipidemia/quercetin 25 mg/kg, hyperlipidemia/quercetin 50 mg/kg, and hyperlipidemia/simvastatin. Animals were pretreated with quercetin for 30 days and hyperlipidemia was subsequently induced by intraperitoneal administration of 500 mg/kg of poloxamer-407. Simvastatin was administered after the induction of hyperlipidemia. Lymphocytes were isolated and E-NTPDase and E-ADA activities were determined. Serum was separated for the cytokines and nucleotide/nucleoside quantification. E-NTPDase and E-ADA activities were increased in lymphocytes from hyperlipidemic rats and pretreatment with quercetin was able to prevent the increase in the activities of these enzymes caused by hyperlipidemia. Hyperlipidemic rats when receiving pretreatment with quercetin and treatment with simvastatin showed decreased levels of ATP and ADP when compared to the untreated hyperlipidemic group. The IFN-γ and IL-4 cytokines were increased in the hyperlipidemic group when compared with control group, and decreased when hyperlipidemic rats received the pretreatment with quercetin. However, pretreatment with quercetin was able to prevent the alterations caused by hyperlipidemia probably by regulating the inflammatory process. We can suggest that the quercetin is a promising compound to be used as an adjuvant in the treatment of hyperlipidemia. |
Databáze: | OpenAIRE |
Externí odkaz: |